• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 23, 2016

View Archived Issues

Financings

Biopharmx Corp., of Menlo Park, Calif., priced an underwritten public offering comprising class A units and class B units. The class A units, priced at 35 cents each, consist of one share of common stock and one seven-year warrant to purchase 0.75 of a share of common stock with an exercise price of 35 cents. Read More

Other news to note

Protalix Biotherapeutics Inc., of Carmiel, Israel, said the Brazilian regulator ANVISA granted approval for alfataliglicerase as a long-term enzyme replacement therapy (ERT) for children, 4 and older, with a confirmed diagnosis of type I Gaucher disease. The ERT was approved for adults in March 2013. Gaucher disease is a rare lysosomal storage disorder, with about 700 patients treated in Brazil. Read More

Regulatory front

With one year to go on the first GDUFA, the FDA finalized a guidance that seeks to answer questions about the user fee agreement that went into effect in 2012 for generic drugs. Read More

Holiday Notice

BioWorld's offices will be closed Thursday, Nov. 24, and Friday, Nov. 25, in observance of the Thanksgiving Day holiday in the U.S. Read More

Industry survey says TGA high in trust, low in feedback, collaboration

PERTH, Australia – Although industry rated Australia's Therapeutics Goods Administration (TGA) high when it comes to performing its role ethically and with integrity, the agency has a ways to go when it comes to communicating with its stakeholders, a recent survey suggests. Read More

Medicine's future is precise, if still uncertain

Reading or hearing about precision medicine can be reminiscent of Dan Ariely's snappy summary of big data analysis, which he said is "like teenage sex: Everyone talks about it, nobody really knows how to do it; everyone thinks everyone else is doing it, so everyone claims they are doing it." Read More

Japan's PMDA taking strides to reduce drug approval timelines

TOKYO – New drug approvals in Japan dropped to a five-year low in 2015, according to the latest report from the PMDA. While reviews are getting faster for standard products, reviews for priority products have grown increasingly longer. Read More

Arog's crenolanib vs. AML, GIST, and more: Can Pfizer licensee win phase III bids?

Privately held Arog Pharmaceuticals Inc. won orphan drug status in Europe for crenolanib to treat acute myeloid leukemia (AML) and soft-tissue sarcoma. An orally available benzimidazole, crenolanib is a type I kinase inhibitor that goes after the signaling of wild-type and mutant isoforms of class III receptor tyrosine kinases FLT3 and platelet-derived growth factor receptor (PDGFR) alpha/beta. Read More

Historic milestone for Zealand Pharma as FDA approves diabetes combo Lixilan

DUBLIN – Zealand Pharma A/S has attained the most significant milestone in its 18-year history, the FDA approval of Sanofi SA's type 2 diabetes combo product, Soliqua 100/33 (insulin glargine and lixisenatide injection, or Lixilan), which adds Zealand's glucagon-like peptide receptor agonist Adlyxin (lixisenatide) to the big pharma firm's basal insulin in a fixed-dose pen. Read More

In the clinic

Neurotrope Inc., of New York, said it started dosing the final patient in the randomized, double-blind, placebo-controlled phase II study testing bryostatin in moderate to severe Alzheimer's disease. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • DNA double helix under a magnifying glass

    23andme genetic privacy concerns garner Congressional scrutiny

    BioWorld MedTech
    The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe